Fig. 6From: Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastomaSurvival analysis depending on treatment in subgroups based on microglial prevalence. Kaplan-Meier survival curves for patients treated with nimotuzumab (nimo) or placebo (cont) in dichotomized subgroups based on Iba1 staining frequency (median split, above median: high, below and equal to median low). P values were calculated using the Wilcoxon testBack to article page